Bristol-Myers Squibb Pharmaceuticals Limited
Manufacture of basic pharmaceutical products · Denham
ActiveUnited KingdomIncorporated 1990Private Limited Company
Financial position
Accounts to 2025-12-31 · GBP · Company accounts
Net assets
£197,901,000
Cash
£524,000
Turnover
—
Profit / loss
£13,055,000
Current assets
£223,209,000
Creditors < 1 year
£73,874,000
Equity
£197,901,000
Average employees
365
Balance-sheet trend
GBP · companyFinancial statements
Selected figures from the best-ranked available filing for each period. Missing values remain unknown.
Some figures were read by AI from scanned accounts, so small errors are possible. View the filed accounts
| Reported figures | 2025-12-31Company · AI-read | 2024-12-31Company · AI-read |
|---|---|---|
| Balance sheet | ||
| Net assets | £197,901,000 | £185,713,000 |
| Equity | £197,901,000 | £185,713,000 |
| Share capital | £50,470,000 | £50,470,000 |
| Retained earnings | £83,575,000 | £71,387,000 |
| Assets | ||
| Fixed assets | £68,628,000 | £58,162,000 |
| Property, plant & equipment | £64,159,000 | £52,886,000 |
| Investments | £4,470,000 | £5,276,000 |
| Current assets | £223,209,000 | £212,094,000 |
| Cash at bank | £524,000 | £376,000 |
| Debtors | £146,226,000 | £111,262,000 |
| Stock | £76,459,000 | £100,457,000 |
| Liabilities | ||
| Creditors within one year | £73,874,000 | £73,366,000 |
| Creditors after one year | £14,000 | — |
| Provisions | £52,834,000 | £46,555,000 |
| Pension scheme surplus / deficit | £32,400,000 | £35,100,000 |
| Net current assets | £149,335,000 | £138,728,000 |
| Assets less current liabilities | £217,963,000 | £196,890,000 |
| Profit & loss | ||
| Profit before tax | £19,221,000 | £18,393,000 |
| Tax | £6,166,000 | £5,000,000 |
| Profit / loss | £13,055,000 | £13,393,000 |
| Operating costs | ||
| Operating lease charges | £2,438,666,000 | £2,911,892,000 |
| People & pay | ||
| Average employees | 365 | 401 |
| Staff costs | £52,628,000 | £56,522,000 |
| Wages & salaries | £40,252,000 | £43,350,000 |
| Social security costs | £5,869,000 | £6,034,000 |
| Pension costs | £3,395,000 | £3,336,000 |
| Directors' remuneration | £739,000 | £669,000 |
| Highest paid director | £467,000 | £378,000 |
| Source evidence | View filing | View filing |
From the accounts
What the accounts for 2025-12-31 say about themselves, read by AI from the scanned filing.
- Auditor
- Deloitte LLP
- Audit opinion
- Clean (unmodified)
- Immediate parent
- Bristol-Myers Squibb Holdings 2002 Limited
- Ultimate parent
- Bristol-Myers Squibb Company
- Ultimate controlling party
- Bristol-Myers Squibb Company
- Accounts
- FRS 102
- Approved
- 2026-07-20, signed by A Ong
Share classes (1)
- 50,470 Ordinary shares of £1 each of £1
Secured borrowing
Registered charges, lenders and security interests.
Charges and related records
0 outstanding chargesNo charges available in our records.